<DOC>
	<DOCNO>NCT00348140</DOCNO>
	<brief_summary>Rosiglitazone ( RSG ) test clinical study approve FDA treatment type II diabetes mellitus , disease occur body unable effectively use glucose . RSG XR , investigational drug use study , extended-release form RSG . This study test whether RSG XR safely provide clinical benefit people mild moderate Alzheimer 's disease ( AD ) combine one currently approve AD medication , Aricept® , Razadyne® Exelon® . RSG XR new approach AD therapy study test new way treat AD test whether one 's genetic makeup affect response study drug . Clinical data suggest RSG may benefit AD patient first see small study perform University Washington large GSK study conduct Europe New Zealand . In first study , subject receive RSG daily 6 month score significantly well 3 test memory think receive RSG . In GSK study , appear benefit treatment RSG XR specific genetic pattern . They gene cause produce protein apolipoprotein E e4 ( APOE e4 ) . Subjects APOE e4 gene may two copy , one parent , may one APOE e4 gene meaning inherit either APOE e2 APOE e3 version gene , instead APOE e4 , one parent . Subjects one copy APOE e4 gene remain level think ability two copy APOE e4 gene , continue worsen 6-month treatment . The current study directly test effectiveness RSG XR people either lack APOE e4 gene .</brief_summary>
	<brief_title>Rosiglitazone ( Extended Release Tablets ) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>A 54-week , double-blind , randomize , placebo-controlled , parallel-group study investigate effect rosiglitazone ( extended release tablet ) adjunctive therapy acetylcholinesterase inhibitor cognition overall clinical response APOE e4-stratified subject mild moderate Alzheimer 's disease ( REFLECT-3 )</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Male female subject clinical diagnosis probable Alzheimer 's disease accordance NINCDSADRDA criterion ( Appendix 2 ) . ( Note : National Institute Neurological Communicative Disorders Stroke ( NINCDS ) Alzheimer 's Disease Related Disorders Association ( ADRDA ) . ) Subject mild moderate Alzheimer 's disease define MMSE score 10 26 inclusive Screening . Hachinski Ischemia Score ≤ 4 Screening ( See Appendix 3 ) . Age ≥50 ≤90 year . At least 6 month ongoing acetylcholinesterase inhibitor therapy Alzheimer 's disease , stable dose least last 2 month ( intent change duration study ) . Current use medication accordance criterion list Table 2 ( Permitted Medications , Section 8.1 ) . Female subject must postmenopausal ( i.e . &gt; 1 year without menstrual period ) , surgically sterile , agree use adequate method contraception ( Appendix 4 ) duration study . Female subject premenopausal postmenopausal &lt; 1 year must undertake pregnancy test ( urine test ) Visit 1 , must negative . Brain CT MRI scan perform within past 12 month Screening , show evidence potential cause dementia Alzheimer 's disease . ( Note : Questionable CT MRI scan discuss medical monitor , use central image guideline . ) Neurological exam without focal change ( exclude change attributable AD peripheral trauma ) . Subject ability comply procedure cognitive test . Subject life ( substantial period contact ) regular caregiver willing attend visit , oversee subject 's compliance protocolspecified procedure study medication , report subject 's status . ( Note : A noncohabiting caregiver must spend sufficient time subject , opinion Investigator , caregiver reliably assess cognitive function , activity behavior , report subject 's compliance health . As caregiver time spend potential subject anticipate highly variable across country culture , GSK consider variety different measure stipulation may meet , GSK consult adequacy caregiver situation doubt . However , guidance , ability caregiver meet his/her expect responsibility study would normally possible caregiver spend less 10 hour per week subject , divide multiple day . ) Subject provide full write informed consent prior performance protocolspecified procedure ; unable provide inform consent due cognitive status , full write informed consent behalf subject provide legally acceptable representative . ( Note : Consent legally acceptable representative allow accordance local law , regulation ethic committee policy . ) Caregiver provide full write informed consent his/her behalf prior performance protocolspecified procedure . Subjects consider enrolment must QTc ( either QTc B ( Bazett 's correction ) QTc F ( Fridericia 's correction ) ) &lt; 450msec Visit 1 , exception subject bundle branch block ( either QTc B QTc F must &lt; 480msec ) . ( Note : For purpose criterion , QTc B define ( QT interval [ msec ] ) / ( square root RR interval [ second ] ) ; QTc F define ( QT interval [ msec ] ) / ( cube root RR interval [ second ] ) . ) A subject eligible inclusion study follow criterion apply : Diagnosis possible , probable , definite vascular dementia accordance NINDSAIREN criterion ( Appendix 5 ) . ( Note : National Institute Neurological Disorders Stroke ( NINDS ) Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) . ) History evidence CNS disorder could interpret cause dementia : e.g . cerebrovascular disease ( stroke , hemorrhage ) , structural abnormality , epilepsy , infectious inflammatory/demyelinating CNS condition , Parkinson 's disease . Evidence follow disorder : current vitamin B12 deficiency , positive syphilis serology , active thyroid dysfunction ( particularly suggestive hypothyroidism ) , include abnormally high low serum level thyroid stimulate hormone ( TSH ) , clinically significant opinion investigator . ( Note : Testing require parameter result available previous 12 month . ) History Type 1 diabetes mellitus secondary diabetes mellitus . Type 2 diabetes mellitus subject treated insulin , PPARγ agonist , insulin secretagogue ( e.g . sulfonylurea glitinide ) . Any patient HbA1c ≥8.5 % . ( See Section 6.3.8.4 Safety Measures Enrolled Subjects Type 2 Diabetes Mellitus . ) History clinical/investigational evidence congestive heart failure define New York Heart Association criterion ( Class I IV cardiac status ; Appendix 6 ) . History cardiovascular event within last 6 month ( i.e . intervention , percutaneous coronary intervention , vascular surgery , acute coronary syndrome [ non Qwave myocardial infarction , Qwave myocardial infarction , unstable angina ] significant arrhythmia ; major intervention ( e.g . cardiac surgery angiography plus stenting ) schedule ) . History significant psychiatric illness schizophrenia bipolar affective disorder opinion Investigator would interfere participation study , major depressive disorder ( accord DSMIV ) past year , current active depression require initiation treatment . ( Note : If currently treat , active depression suspect , Cornell Scale Depression Dementia ( CSDD , Appendix 7 ) use Investigator guide decide whether prospective subject require treatment . If subject CSDD score &gt; 7 , Investigator decide subject depression need prescribe medication , CSDD &gt; 12 consider strong indicator treatment need . Subjects allow rescreen depression adequately manage &gt; 3 month . ) History presence gastrointestinal , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug , clinically relevant abnormality , medical psychiatric condition , , opinion Investigator , make subject unsuitable inclusion study . Clinically significant peripheral edema time screen . Current recent drug alcohol abuse dependence ( define DSMIV criterion substancerelated disorder ) , recent remote history could contribute factor dementia . Systolic blood pressure &gt; 165 &lt; 90 mmHg diastolic blood pressure &gt; 95 &lt; 60 mmHg time screen . Clinically significant anemia ( i.e . hemoglobin &lt; 11 g/dL male &lt; 10 g/dL female ) presence hemoglobinopathy would prevent accurate assessment HbA1c . Abnormal kidney function test ( &gt; 1.5 time upper limit normal ( ULN ) ) . ALT , AST , alkaline phosphatase value &gt; 2.5 time ULN , total bilirubin value &gt; 1.5 time ULN , history severe hepatobiliary disease ( e.g . hepatitis B C , cirrhosis , ChildPugh Class B/C ) . ( Note : For subject diagnosis Gilberts Syndrome isolate increase total bilirubin &gt; 1.5 ULN , fractionation perform . If following condition meet , patient may enter remain study , even total bilirubin &gt; 1.5 ULN : elevate unconjugated ( indirect ) bilirubin ; percentage direct bilirubin &lt; 35 % ; ALT , AST , alkaline phosphatase &lt; 2.5 ULN subject screening ( &lt; 2.0 ULN Canadian subject ) , ≤3 ULN subject already randomize study ) History bone marrow transplant . Subject unable ( assistance , appropriate ) take study medication prescribe throughout study risk noncompliance study medication procedure . Subject immediate family member employee participate Investigator , participate site staff , GSK . In France , subject neither affiliated beneficiary social security category . The French subject participate study use investigational drug previous 30 day 5 halflives ( whichever longer ) . Cognitive task prescribe cognitive rehabilitation perform medical supervision prohibit 6 month prior Screening , well duration study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adjunctive therapy</keyword>
	<keyword>moderate</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>apolipoprotein E</keyword>
	<keyword>mild</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>cognition</keyword>
</DOC>